Galmed jumps on lab data on new brain-penetrating version of experimental drug

Eocene

09/04/2026 13:05

** Shares of biotech firm Galmed Pharmaceuticals GLMD.O jump 68% to $1.05 premarket

** Co says it developed a new formulation of its experimental drug Aramchol that can reach the brain, targeting Parkinson's and similar brain diseases that affect movement and thinking

** Co says lab tests showed the new version lowered levels of a disease-linked protein and was not toxic in early studies

** The new formulation uses tiny fat-based particles to help the drug cross the brain's natural protective barrier, co says

** Co plans early-stage human trials in the second half of 2026, pending regulatory approval - GLMD

** Parkinson's is a brain disorder where harmful proteins build up and slowly damage nerve cells; there are no treatments that slow the disease

** As of last close, stock was down ~17% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))